Moderna fends off Alnylam US patent lawsuit over COVID shots, for now
Alnylam Pharmaceuticals admitted defeat, for now, in a lawsuit in Delaware federal court that accused Moderna's blockbuster ...
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and Moderna, Inc. (NASDAQ:MRNA) have reached a stipulation in their ongoing ...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Is Expected To Breakeven In The Near Future
With the business potentially at an important milestone, we thought we'd take a closer look at Alnylam Pharmaceuticals, ...
Zacks.com on MSN3d
Here's Why You Should Add ALNY Stock to Your Portfolio Right Now
Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of ...
Biogen, Alnylam-partnered Camp4 Therapeutics unveils IPO plans
Camp4 Therapeutics Inc., a Cambridge biotech that has already struck deals with Biogen Inc. and Alnylam Pharmaceuticals Inc., ...
Alnylam : Phase 3 Study Data Support Potential Of Vutrisiran In ATTR Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals Inc. (ALNY) said that new data from the HELIOS-B Phase 3 study of vutrisiran showed that the drug attenuated ...
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,300 Today
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $1,295.68 today based on a ...
Alnylam Pharma’s Promising Clinical Data Tempered by Market Factors in Hold Rating Assessment
Michael Ulz, an analyst from Morgan Stanley, maintained the Hold rating on Alnylam Pharma (ALNY – Research Report). The associated price ...
TCTMD1d
Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM
Two new analyses from HELIOS-B answer important questions, but some uncertainties remain, says Julie Rosenthal.
The Pharma Letter5d
New Alnylam HELIOS-B vutrisiran data presented at HFSA
US RNAi therapeutics company Alnylam Pharmaceuticals has released two new data sets from the HELIOS-B Phase III study of ...
Nasdaq6d
Alnylam : Phase 3 Study Data Support Potential Of Vutrisiran In ATTR Amyloidosis With Cardiomyopathy
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) said that new data from the HELIOS-B Phase 3 study of vutrisiran showed that the drug attenuated measures of disease progression across multiple ...